About this Research Topic
As our understanding of the pathogenesis of cancers grows and new treatment modalities become available, so too does the number of key research questions in oncology that need answering. Frontiers in Oncology is working with members of our Editorial Board to tackle some of these key questions through Editor’s Challenges, each of which pose a key question in the oncology field.
We are delighted to present this Editor’s Challenge, led by Dr. Claudio Cerchione, and in collaboration with Prof. Kenneth Anderson, asking if it is time for a targeted therapy in multiple myeloma?
The Current State of Targeted Therapies in Myeloma
Although the myeloma treatment landscape has expanded with the introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal and bispecific antibody therapies, and CAR-T, the disease remains incurable. Currently, considering the heterogeneity of this disease, there are not strictly any targeted therapies available for multiple myeloma, with therapies instead working through pathways common to all plasma cells.
Next-generation sequencing and other sensitive technologies have revealed the genetic complexity of myeloma progression and treatment response. This has also led to the exploration of novel targeted approaches. Emerging targets are BCMA (i.e. belantamab, bispecific antibodies, and CAR-T), XPO1 (selinexor), as well as t(11;14) for venetoclax-based treatments.
This Research Topic invites Original Research, Clinical Trial, and Review type manuscripts contributing to the exploration and advancement of profiling, potential targets and targeted therapies in multiple myeloma.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Other collections in our Editor's Challenge series:
Editor's Challenge: Abhishek Mahajan - How Can Precision Oncology be Advanced with Validated Imaging-Based Nomograms?
Editor's Challenge: Mohamed Rahouma - How Can We Optimize the Management and Treatment of Cardiac Tumors and Cardiac Complications of Cancer?
Editor's Challenge: Dr. Luciano Mutti - What Is the True Impact of ICIs on Survival in the Treatment of Thoracic Malignancies?
Editor's Challenge: Editor's Challenge: Walter Storkus - Sexual Dimorphism and the Host Immune Response to Renal Cell Carcinoma
Editor's Challenge: Dr. Qingxin Mu - How can Nanomedicine Approaches Advance Multi-targeting Strategy in Combination Cancer Therapy?
We are delighted to present this Editor’s Challenge, led by Dr. Claudio Cerchione, and in collaboration with Prof. Kenneth Anderson, asking if it is time for a targeted therapy in multiple myeloma?
The Current State of Targeted Therapies in Myeloma
Although the myeloma treatment landscape has expanded with the introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal and bispecific antibody therapies, and CAR-T, the disease remains incurable. Currently, considering the heterogeneity of this disease, there are not strictly any targeted therapies available for multiple myeloma, with therapies instead working through pathways common to all plasma cells.
Next-generation sequencing and other sensitive technologies have revealed the genetic complexity of myeloma progression and treatment response. This has also led to the exploration of novel targeted approaches. Emerging targets are BCMA (i.e. belantamab, bispecific antibodies, and CAR-T), XPO1 (selinexor), as well as t(11;14) for venetoclax-based treatments.
This Research Topic invites Original Research, Clinical Trial, and Review type manuscripts contributing to the exploration and advancement of profiling, potential targets and targeted therapies in multiple myeloma.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Other collections in our Editor's Challenge series:
Editor's Challenge: Abhishek Mahajan - How Can Precision Oncology be Advanced with Validated Imaging-Based Nomograms?
Editor's Challenge: Mohamed Rahouma - How Can We Optimize the Management and Treatment of Cardiac Tumors and Cardiac Complications of Cancer?
Editor's Challenge: Dr. Luciano Mutti - What Is the True Impact of ICIs on Survival in the Treatment of Thoracic Malignancies?
Editor's Challenge: Editor's Challenge: Walter Storkus - Sexual Dimorphism and the Host Immune Response to Renal Cell Carcinoma
Editor's Challenge: Dr. Qingxin Mu - How can Nanomedicine Approaches Advance Multi-targeting Strategy in Combination Cancer Therapy?
Keywords: myeloma, targeted therapy, immunotherapy, genetics, genomics, t(4;14), FGFR3, MMSET, BRAF, TP53, RB1, CDK2NC, monoclonal antibodies, bispecific antibodies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
